Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orion corporation - budesonid, formoterolfumarat dihydrat - inhalationspulver - 9+320 mikrog/dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - budesonid, formoterolfumarat dihydrat - inhalationspulver - 9+320 mikrog/dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - salbutamolsulfat - inhalationsvæske til nebulisator, opløsning - 1mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

europharma.dk aps - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+80 mikrog./dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

abacus medicine a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis

Den Europæiske Union - dansk - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

astrazeneca a/s - budesonid, formoterolfumarat dihydrat - inhalationsspray, suspension - 4,5+160 mikrog/dosis